Genta Inc., of Berkeley Heights, N.J., said it has accrued its first patient in a trial of tesetaxel as initial chemotherapy for advanced or recurrent breast cancer. The randomized Phase IIb trial will enroll approximately 220 patients at 15 sites in the U.S. and Western Europe.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter